Comorbidity and beyond: Pre-transplant clinical assessment

Bone Marrow Transplantation

Volumn 36, Issue 6, 2005, Pages 473-474

  Artz, A S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; COMORBIDITY; EDITORIAL; GERIATRIC CARE; GRAFT VERSUS HOST REACTION; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TREATMENT INDICATION;

COMORBIDITY; HEALTH STATUS INDICATORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PATIENT SELECTION; RISK ASSESSMENT;

EID: 31044436327     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705042     Document Type: Editorial

References (12)

1. Van Besien K, Artz A, Stock W. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia 2005; 19: 31-33.
2. Yancik R, Havlik RJ, Wesley MN et al. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 1996; 6: 399-412.
3. Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003; 46: 211-220.
4. Alamo J, Shahjahan M, Lazarus HM et al. Comorbidity indices in hematopoietic stem cell transplantation: A new report card. Bone Marrow Transplant 2005; 36: 475-479.
5. Sorror ML, Maris MB, Storer B et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
6. Diaconescu R, Flowers CR, Storer B et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
7. Pollyea DA, Artz AS, Stock W et al. Clinical predictors of transplant related mortality after reduced intensity conditioning allogeneic stem cell transplantation (RIST). Blood 2004; 104 (abstract 1145).
8. Shahjahan M, Alamo J, de Lima M, Khouri I. Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission. Biol Blood Marrow Transplant 2004; 10 (Supplement) 1.
9. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
10. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1836.
11. Giralt S, Thall PF, Khouri T et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
12. Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089-1095.